chemXplore tracks 14 projects in Japan, of which 13 are active.
9 new construction, 3 expansion, and 1 revamp / retrofit.
2 of the active projects carry no start-up date yet.
Owners and developers: Asahi Kasei Corporation (2), Mitsubishi Chemical Group (2), X-ELIO Energy, S.L. (2), AGC Biologics S.p.A. (1), AGC Group (1), Air Liquide SA (1)
Investors: Ministry of Economy, Trade and Industry (3), Brookfield Corporation (2), AGC Group (1), Air Liquide SA (1), Asahi Kasei Corporation (1), Kyushu Electric Power Co., Inc. (1)
Contractors, licensors, and offtakers are recorded on 6 of these 13 projects For subscribers
Targeting: Argon (1), Carbon (1), Carbon dioxide (1), Hydrogen (1), Lithium bis(fluorosulfonyl)imide (1), Methane (1)
BLA for I‑DXd seeking accelerated approval in extensive‑stage SCLC withdrawn after FDA said Phase 2 data were insufficient; Phase 3 programmes continue.
Oral baricitinib showed substantial scalp, eyebrow and eyelash regrowth in a Phase 3 pediatric trial; 4 mg and 2 mg doses outperformed placebo at Week 36.
Single CARVYKTI infusion produced treatment-free, progression-free remissions at five years in half of early-line relapsed/refractory multiple myeloma patients.
Phase 4 STAR trial: guselkumab improved BASDAI at Week 24, reduced ASDAS‑CRP and MRI sacroiliac inflammation in biologic‑naïve axial PsA; safety profile consistent.
New 498 GT chemical tanker to transport and bunker methanol; initial bunkering used biomethanol from Niigata plant; methanol fuel cuts CO2 by ~17.5% vs heavy fuel oil.
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
Third line comprises 2,300 t/d ammonia and 4,000 t/d single-line urea (ACES21™); built adjacent to existing Port Harcourt complex; awarded 2023, completed June 2026.
First subcutaneous immune‑checkpoint inhibitor in Japan; can be given in as little as one minute and showed comparable exposure and response to IV pembrolizumab in a phase‑3 trial.
Four-way MoC creates a regional centre for testing, verification, training, R&D and knowledge sharing on methane measurement technologies in Southeast Asia.
Interim analysis shows a significant progression‑free survival benefit versus rituximab+lenalidomide in second‑line or later relapsed/refractory follicular lymphoma; safety as expected.
